Tenecteplase

Lys Therapeutics Surpasses €25 Million in Funding and Advances LYS241 Toward Clinical Development Across Neurological Indications Over €25 million raised since company inception from private investors, public institutions, international foundations and public innovation programs Funding momentum strengthened by the arrival of new investors: Normandie Participation, TCD Capital and FIDAT Ventures Resources intended to finalize regulatory studies, secure industrial manufacturing, and support LYS241’s entry into clinic, as part of a biomarker-rich Phase 1a/1b program with indication-specific cohorts across several neurological diseases. Lyon & Caen, France, June 22, 2026 – Lys Therapeutics, a French biotechnology company pioneering an innovative approach targeting the tPA-NMDAr axis to treat neurodegenerative and neurovascular diseases, today announced that it has raised more than €25 million since its founding in 2021. In five years, the company has achieved several key preclinical, regulatory, industrial and translational maturation milestones, creating the conditions required to advance LYS241 into the clinic. This major milestone reflects the confidence of investors and institutional partners in the technology developed by Lys Therapeutics and in the therapeutic potential of its drug candidate LYS241. The funding secured combines equity investments, non-dilutive public funding and support from international foundations dedicated to biomedical research. These supporters include the Michael J. Fox Foundation for Parkinson’s Research, a U.S.-based foundation that recently awarded Lys Therapeutics a grant of more than $5 million to accelerate the clinical development of LYS241 in Parkinson’s disease. This momentum is also supported by several selective public programs backing breakthrough healthcare innovation, including Bpifrance and France 2030. Strengthening of the shareholder base This growth momentum is accompanied by the arrival of new strategic investors in the company’s share capital: Normandie Participation, the investment fund of the Normandy Region, TCD Capital (The Club Deal), an investment fund backed by European private investors, as well as FIDAT Ventures, the Oddo family investment vehicle. They join Lys Therapeutics’ historical investors, including ZCUBE, the investment vehicle of the pharmaceutical group Zambon, as well as Philippe Bissay, Chairman and Chief Executive Officer of HAC Pharma. Solid financing to support the transition into the clinic Thanks to the resources raised, Lys Therapeutics is currently conducting the regulatory studies required to launch the first clinical trials in humans. A biomarker-rich Phase 1a/1b clinical program is in preparation. It is expected to combine healthy volunteer cohorts and indication-specific patient cohorts, in order to document safety, pharmacokinetics and early proof-of-biology signals across several priority indications. Recent advances in several priority indications Parkinson’s disease: the $5 million grant awarded by the Michael J. Fox Foundation is part of the increasing scientific and translational validation of the program. Recent preclinical data support the potential of LYS241 to act on BBB dysfunction, neuroinflammation and neurodegenerative progression. Synucleinopathies, including multiple system atrophy: beyond Parkinson’s disease, Lys Therapeutics is continuing to explore the potential of LYS241 in synucleinopathies, including multiple system atrophy, where new preclinical data confirm the relevance of this approach. Ischemic stroke: Lys Therapeutics is developing LYS241 as a standalone or complementary approach to standard reperfusion therapies, including thrombolytics (alteplase, tenecteplase) and mechanical thrombectomy. Preclinical data support the potential of this approach to preserve BBB integrity, improve reperfusion quality, and reduce the hemorrhagic and inflammatory complications associated with pathological neurovascular effects driven by tPA-NMDAr pathway activation. A strengthened translational, industrial and strategic package The company is also strengthening its translational package through human tissue analyses, genetic approaches and biomarkers aimed at documenting the role of the tPA-NMDAr axis in the targeted neurological diseases. Lys Therapeutics has also consolidated its industrial strategy to secure the large-scale production of LYS241 batches, a key milestone to support the program’s transition toward clinical proof of concept. Over the past few months, the company has also advanced its governance and medical advisory support to underpin its clinical strategy. These advances are accompanied by increasing international visibility among foundations, expert clinicians, specialized investors and pharmaceutical partners. Developed through a unique approach, LYS241 aims to restore BBB integrity, limit neuroinflammatory processes and protect brain tissue. By targeting a vascular mechanism shared by several acute and chronic neurological diseases, LYS241 supports a development strategy known as ‘pipeline-in-a-product’, with expansion potential beyond a single indication. “Raising more than €25 million in only five years is a strong recognition of the quality of our science, the relevance of our therapeutic approach and the broad potential of LYS241. This financial support gives us the means to pursue the regulatory studies and finalize preparation of a Phase 1a/1b clinical program. The recent advances achieved in Parkinson’s disease, synucleinopathies and ischemic stroke reinforce our conviction that LYS241 can become a cross-indication therapeutic platform for several severe neurological diseases. Our ambition is to translate differentiated biology into a new class of treatments capable of modifying the course of diseases for which medical needs remain considerable,” said Dr. Manuel Blanc, CEO and co-founder of Lys Therapeutics. About LYS241 LYS241 is a fully humanized IgG1 monoclonal antibody with a silent Fc backbone, designed to block the pathological interaction between tPA and NMDA receptors. By targeting this tPA-NMDAr pathway, LYS241 aims to neutralize key mechanisms involved in neurovascular dysfunction, blood-brain barrier (BBB) disruption, neuroinflammation and excitotoxicity, which contribute to the progression of numerous neurological diseases. This differentiated mechanism translates into broad therapeutic potential: Parkinson’s disease: LYS241 is being developed as a potentially disease-modifying approach designed to act upstream on neurovascular dysfunction, BBB disruption and neuroinflammation. Preclinical data support its potential to slow disease progression and preserve motor function, with the objective of complementing current symptomatic treatments. Synucleinopathies, including multiple system atrophy: LYS241 has differentiating potential in rapidly progressive synucleinopathies, particularly multiple system atrophy, an orphan disease with high unmet medical need and no approved disease-modifying treatment to date. The preclinical data generated support the relevance of this approach to target mechanisms of neurovascular dysfunction and neuroinflammation, with the objective of slowing disease progression and preserving motor and autonomic functions. Ischemic stroke: LYS241 is being developed as a standalone or complementary approach to standard thrombolytic agents (alteplase / tenecteplase) and mechanical thrombectomy, with the objective of preserving cerebral vascular integrity, improving the quality of reperfusion, and reducing hemorrhagic and inflammatory complications. By targeting a unifying neurovascular mechanism, Lys Therapeutics is deploying a pipeline-in-a-drug strategy aimed at fully leveraging the therapeutic potential of LYS241 across a broad spectrum of neurological diseases with high unmet medical need. About Lys Therapeutics Next-generation biotherapies for neurological diseases. Lys Therapeutics is an advanced preclinical-stage biotechnology company developing innovative monoclonal antibodies to treat patients with severe neurodegenerative and neurovascular diseases associated with significant unmet medical needs. The company targets upstream biological determinants, shared across several major neurological indications, at the intersection of neurovascular dysfunction, neuroinflammation and excitotoxicity. Its lead candidate, LYS241, is a fully humanized monoclonal antibody with a unique mechanism of action that selectively blocks the pathological interaction between tissue plasminogen activator (tPA) and NMDA receptors (NMDAr), while preserving the physiological function of these receptors. By dissociating this key neurovascular axis, LYS241 simultaneously restores blood-brain barrier integrity, reduces neuroinflammation and protects both vascular and neuronal compartments. Headquartered in Lyon and Caen (France), and leveraging strong collaborations with leading international academic institutions, Lys Therapeutics is deploying a pipeline-in-a-product strategy centered on LYS241. The company is supported by prestigious partners, including The Michael J. Fox Foundation, Bpifrance and private investors.

ST. LOUIS, May 28, 2026 /PRNewswire/ -- Whether at home or in the hospital, quickly recognizing the signs of stroke is key to saving brain tissue. Peter Marsac, 58, was at Mercy Hospital St. Louis recovering from a severe reaction to an ACE inhibitor when an occupational therapist noticed subtle left-sided weakness. "I was in the right place at the right time," said Marsac, who is chief of Maplewood (Mo.) Fire Department. "I'm very thankful, God was on my side." Marsac suffered an ischemic stroke, the most common type of stroke, caused by a blockage in a blood vessel leading to the brain. "After recovering from the severe swelling and two days in a coma, I began inpatient rehab. I was working on basic motor skills with my occupational therapist when something didn't feel right," Marsac said. "She asked me to stand up, march in place and I couldn't lift my left leg – it felt like it was full of cement." Cat Morroney, occupational therapist at Mercy St. Louis, began reviewing the stroke warning signs with him and knew she needed to activate the stroke team. Within minutes, Marsac was diagnosed and treated with a clot-busting medication, which made the difference in his outcome. Marsac credits Morroney with his quick treatment, "By the time I was taken down for a CT, my arms had gone numb – though everything returned within 24 hours. I'm thankful the pieces fell into place and that Cat advocated for me. She should be recognized." While Marsac spent a week in the intensive care unit related to his blood pressure, he has no lasting impacts from the stroke because his condition was noticed and treated quickly with Tenecteplase, also called TNK, a clot-busting drug. "For every minute a stroke is left untreated, a million nerve cells in the brain die," said Dr. Nida Jamal, neurologist and stroke team medical director at Mercy St. Louis. "That's why we say, 'Time is brain.' The faster you act, the better the outcome for the patient." It's important to know the signs and symptoms of a stroke to ensure treatment begins as soon as possible. The acronym to remember is B.E. F.A.S.T. because when it comes to spotting a stroke and getting help, the faster the better. B – Balance Loss: Is there a sudden loss of balance or coordination? Is the person having trouble walking or experiencing dizziness? E – Eye (Vision) Changes: Are there sudden changes in vision? Ask the person if they are experiencing blurred vision, double vision or loss of sight in one or both eyes. F – Face Drooping: Does one side of the face droop or is it numb? Ask the person to smile, is smile uneven? A – Arm Weakness: Is one arm weak or numb? Ask the person to raise both arms. Does one arm drift downward? S – Speech Difficulty: Is speech slurred or difficult to understand? Ask the person to repeat a simple sentence. T – Time to Call 911: If you have any of these symptoms or see someone else having them, call 911 immediately. Mercy, one of the 15 largest U.S. health systems and named the top large system in the U.S. for excellent patient experience by NRC Health, serves millions annually with nationally recognized care and one of the nation's largest and highest performing Accountable Care Organizations in quality and cost. Mercy is a highly integrated, multi-state health care system including 55 acute care and specialty (heart, children's, orthopedic and rehab) hospitals, convenient and urgent care locations, imaging centers and pharmacies. Mercy has over 1,000 physician practice locations and outpatient facilities, more than 5,000 physicians and advanced practitioners and more than 50,000 caregivers serving patients and families across Arkansas, Illinois, Kansas, Missouri and Oklahoma. Mercy also has clinics, outpatient services and outreach ministries in Arkansas, Louisiana, Mississippi and Texas. In fiscal year 2025 alone, Mercy provided more than half a billion dollars of free care and other community benefits, including traditional charity care and unreimbursed Medicaid. SOURCE Mercy 21% more press release views with Request a Demo